Clinical trials: Breast Neoplasms, Triple-Negative
Platinum-sensitive, TNBC, Triple Negative Breast Cancer
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
Breast cancer is the most common malignancy in women; approximately 5-10% are hereditary, with 14% of triple-negative breast cancers (TNBC) harboring BRCA mutations.
- Conditions
- Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not
- Trial name
- Fzp-MA-TNBC (NCT07321015)
- Testing
- Fluzoparib Monotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Arsenous Acid for Refractory Triple-Negative Breast Cancer
The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of…
- Trial name
- NCT06678048
- Testing
- Arsenous Acid plus Chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-sen University
Breast Neoplasms
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
The purpose of the study is to address the following hypotheses: (i) Anti-PD-L1 therapy with MEDI4736 administered concomitantly with weekly nab-paclitaxel followed by MEDI4736 concomitant with ddAC neoadjuvant chemotherapy will…
- Trial name
- NCT02489448
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Yale University
TNBC
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.
- Trial name
- NCT05918133
- Testing
- PM8002, nab-paclitaxel
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Biotheus Inc.
Breast Cancer
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00930930
- Testing
- cisplatin, everolimus, paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 145 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Neoplasms, Triple Negative Breast Neoplasms
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Researchers are looking for new ways to treat types of breast cancer that are both: High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment Early-stage, which means the cancer is…
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
- Trial name
- NCT06966700
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 331 sites in United States, Argentina and 39 more
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Cancer, HER2-negative Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06999187
- Testing
- DR-0202
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Dren Bio
Breast Cancer, Triple Negative Breast Cancer
Emotions Immunology and Breast Cancer
Pilot study representing a proof of concept regarding the potential for immune system enhancement with psychotherapy, resulting in improved immunological response at lumpectomy or mastectomy in patients undergoing neoadjuvant…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Emotions, Immunology
- Trial name
- NCT03609671
- Testing
- Standard of Care + Experimental Individualized Therapy, Control: Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Luz A. Venta, MD
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
This phase II trial studies how well estradiol works in treating patients with estrogen receptor beta (ER beta) positive, triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or other…
- Conditions
- Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT03941730
- Testing
- Biopsy, Computed Tomography, Magnetic Resonance Imaging
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Breast Neoplasms
BRCA Mutations in Latinas
Background: BRCA1 and BRCA2 gene mutations have been linked to a higher risk of developing breast cancer and other cancers, and may be associated with types of breast cancer that are more difficult to treat and more likely to…
- Trial name
- NCT01251900
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- National Cancer Institute (NCI)
TNBC, Triple Negative Breast Cancer
TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
Refining neoadjuvant chemoimmunotherapy and establishing predictive biomarkers remain pivotal challenges in early TNBC. Although SG/I (sacituzumab govitecan/PD-1 inhibitor) shows clinical promise, validation of responder…
- Trial name
- TREND-02 (NCT07271992)
- Testing
- SG+I
- Volunteers
- 30 people
- Sponsor
- First Hospital of China Medical University
Breast Cancer
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
The main objective of the trial is to compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab.
- Trial name
- NCT00528567
- Testing
- Bevacizumab, Standard adjuvant chemotherapy
- Where
- 403 sites in United States, Argentina and 38 more
- Volunteers
- 2,591 people
- Sponsor
- Hoffmann-La Roche
TNBC - Triple-Negative Breast Cancer
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer
This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for…
- Trial name
- NCT07256964
- Testing
- Toripalimab, PCb-EC, PCb
- Volunteers
- 216 people
- Sponsor
- Henan Cancer Hospital
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
This phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor positive triple-negative breast…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07016399
- Testing
- Biospecimen Collection, Breast Biopsy Procedure, Carboplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Vandana Abramson
Breast Cancer, Triple Negative Breast Cancer
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
This study will test the effectiveness of two standard neoadjuvant chemotherapy regimens plus an investigational drug (ivonescimab) that has dual action as both immunotherapy and therapy targeting the tumor's blood supply.
- Trial name
- NeoASPECT (NCT07743632)
- Testing
- Carboplatin, Docetaxel, Doxorubicin
- Volunteers
- 110 people
- Sponsor
- University of Kansas Medical Center
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer…
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative
- Trial name
- NCT02208375
- Testing
- Capivasertib, Laboratory Biomarker Analysis, Olaparib
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- M.D. Anderson Cancer Center
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
This phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating patients with newly diagnosed triple negative breast cancer that is limited to the breast and possibly to the nearby lymph nodes…
- Conditions
- Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
- Trial name
- NCT02593175
- Testing
- Carboplatin, Paclitaxel, Panitumumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Triple Negative Breast Cancer
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that lacks the expression of ER, PR, and Her-2 proteins, accounting for 15%-20% of all breast cancers.TNBC patients do not benefit from endocrine therapy…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Camrelizumab
- Trial name
- NCT05475678
- Testing
- （Carrelizumab + TCb） regimen, TCb regimen
- Where
- China
- Volunteers
- 369 people
- Sponsor
- Zhenzhen Liu
Solid Tumor, Adult
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors.
- Trial name
- NCT04551885
- Testing
- FT516, Avelumab, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fate Therapeutics
Breast Neoplasm
Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.
- Trial name
- NCT01015521
- Testing
- Aminoflavone Prodrug
- Volunteers
- 50 people
- Sponsor
- Tigris Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.